InvestorsHub Logo
Followers 91
Posts 11363
Boards Moderated 0
Alias Born 06/06/2014

Re: groton68 post# 216508

Thursday, 02/08/2018 2:33:36 PM

Thursday, February 08, 2018 2:33:36 PM

Post# of 403093
No. The company made no mention of it "meeting all endpoints." There was in fact no mention of plasma concentrations or tumor response. They did see signs of p53 activity, which is encouraging. In this aspect, the trial was a success. Hopefully it was the limited dosing regimen that obviated efficacy outcomes. It was the reason the company discontinued the trial. (Yeah yeah we know, the results were so darn good that we decided not to spend any more money on it. That's some folks idea of dealing with reality.)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News